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Breast cancers with lactating features, some of which are associated with pregnancy and
lactation, are often poorly differentiated, lack estrogen receptor, progesterone receptor,
and HER2 expression and have high mortality. Very little is known about the molecular
mechanisms that drive uncontrolled cell proliferation in these tumors and confer lactating
features. We have recently reported expression of OCT4 and associated embryonic stem
cell self-renewal genes in the normal lactating breast and breastmilk stem cells (hBSCs).
This prompted us to examine OCT4 expression in breast cancers with lactating features
and compare it with that observed during normal lactation, using rare specimens of human
lactating breast. In accordance with previous literature, the normal resting breast (from
non-pregnant, non-lactating women) showed minimal OCT4 nuclear expression (0.9%).
However, this increased in the normal lactating breast (11.4%), with further increase in
lactating adenomas, lactating carcinomas, and pregnancy-associated breast cancer (30.7–
48.3%). OCT4 was expressed in the epithelium and at lower levels in the stroma, and
was co-localized with NANOG. Comparison of normal non-tumorigenic hBSCs with OCT4-
overexpressing tumorigenic breast cell lines (OTBCs) demonstrated upregulation of OCT4,
SOX2, and NANOG in both systems, but OTBCs expressed OCT4 at significantly higher
levels than SOX2 and NANOG. Similar to hBSCs, OTBCs displayed multi-lineage differenti-
ation potential, including the ability to differentiate into functional lactocytes synthesizing
milk proteins both in vitro and in vivo. Based on these findings, we propose a hypothe-
sis of normal and malignant transformation in the breast, which centers on OCT4 and its
associated gene network. Although minimal expression of these embryonic genes can be
seen in the breast in its resting state throughout life, a controlled program of upregulation
of this gene network may be a potential regulator of the normal remodeling of the breast
toward a milk-secretory organ during pregnancy and lactation. Deregulation of this gene
network either within or outside pregnancy and lactation may lead to aberrant breast cell
proliferation and malignant transformation, suggesting a role of these genes in both normal
lactation and breast oncogenesis.
Keywords: mammary gland, breastmilk, breast cancer, transcription factors, OCT4, adult stem cell, cancer stem
cell, self-renewal
INTRODUCTION
Breast cancer associated with pregnancy and lactation (PABC,
defined as concurrent with or within 1 year from pregnancy and
lactation) is the most frequent malignancy in pregnant women,
affecting 1:3000 pregnancies in patients between 32 and 38 years
old (Keleher et al., 2002; Gentilini et al., 2005; Barnes and Newman,
2007; Keinan-Boker et al., 2008). Because this cancer is age-related,
its incidence is increasing as many women delay childbearing until
later in life (Barnes and Newman, 2007; Keinan-Boker et al., 2008).
These cancers often display lactating features, which are sometimes
also noted in breast tumors that arise outside pregnancy/lactation,
and have not yet been molecularly characterized. They are gener-
ally triple negative and are diagnosed at late stages, typically having
poor prognosis (Barnes and Newman, 2007). It is therefore impor-
tant to understand the pathogenesis of these cancers and elucidate
the molecular mechanisms associated with aberrant cell prolifera-
tion and lactating features both within and outside pregnancy and
lactation.
Normal self-renewal is regulated by a number of genes, which
when deregulated may lead to aberrant cell proliferation. OCT4 is
a self-renewal transcription factor (TF) that is found silenced in
the vast majority of somatic cells. It has been established that the
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normal resting breast (from non-pregnant, non-lactating women)
as well as cell lines derived from it have very little expression of
OCT4 and associated embryonic TFs (Tai et al., 2005; Beltran et al.,
2011; Lengerke et al., 2011; Hassiotou et al., 2012; Liu et al., 2012).
However, we have recently demonstrated high expression of OCT4
and its associated TFs in the normal lactating breast and in cells
isolated from breastmilk (Hassiotou et al., 2012). OCT4 is a key
TF, which together with SOX2 and NANOG regulates self-renewal
and pluripotency in embryonic stem cells (ESCs) (Boyer et al.,
2005; Young, 2011). In addition, ectopic expression of OCT4 and
other embryonic TFs (such as SOX2 and KLF4) reprograms adult
somatic cells to a self-renewing, undifferentiated pluripotent state,
named induced pluripotent stem cell (iPSC) (Sterneckert et al.,
2012). In addition to ESCs and iPSCs, an increasing body of evi-
dence demonstrates expression of OCT4 and its associated ESC
TFs in various adult organs by rare subpopulations of normal
stem cells (Tai et al., 2005; Matthai et al., 2006; Conrad et al., 2008;
Kuroda et al., 2010; Arnold et al., 2011; Nakatsugawa et al., 2011;
Ratajczak et al., 2011), including the breast both in its resting (Has-
siotou et al., 2012; Roy et al., 2013) and lactating state (Hassiotou
et al., 2012). The common expression of ESC TFs in the early adult
stem cell state and their downregulation upon differentiation sug-
gest molecular similarities between the regulation of ESCs and the
cell population associated with repair, regeneration, and remodel-
ing in some adult tissues. At the same time, aberrant upregulation
of ESC TFs in certain cancers and association with cancer stem-
like cell (CSC) proliferation further reinforce ESC TF involvement
in both normal adult tissue development and oncogenesis (Monk
and Holding, 2001; Kumar et al., 2012).
Previous work has demonstrated expression of OCT4, SOX2,
and NANOG in some breast tumors, particularly triple negative
cancers that are poorly differentiated and have poor prognosis
(Ben-Porath et al., 2008; Lengerke et al., 2011; Liu et al., 2011,
2012). However, the large heterogeneity and variability in expres-
sion both between and within tumor tissues make the association
of these genes with breast cancer still obscure (Liu et al., 2011; Leis
et al., 2012). Expression of OCT4 in the normal lactating breast
prompted us to examine whether OCT4 is also expressed in breast
tumors with lactating features and/or associated with pregnancy
and lactation. We hypothesized that OCT4 expression is associated
with lactating features both in the normal breast during lactation
and in breast tumors that display such features.
To address this, we quantified OCT4 expression and subcellular
localization by immunohistochemical (IHC) staining in rare spec-
imens of normal human breast during the resting (non-lactating)
and lactating stages, and in breast cancers with lactating features.
Although minimal OCT4 expression was observed in the nor-
mal resting breast, OCT4 was upregulated in the normal lactating
breast, with a further increase in expression in breast tumors with
lactating features. The majority of OCT4+ cells in tumor and nor-
mal lactating tissues co-expressed NANOG. To further investigate
the association of OCT4 with normal and aberrant breast devel-
opment, we compared expression of OCT4 and associated ESC
genes between hESCs and normal self-renewing stem cells accessed
via breastmilk (hBSCs) or available OCT4-overexpressing breast
cancer cell line models (OCT4-overexpressing tumorigenic breast
cell lines, OTBCs) possessing tumor-initiating features. Although
expression levels between ESC genes were similar in both hBSCs
and hESCs, OTBCs had imbalanced ESC gene expression, with
OCT4 levels being significantly higher than those of SOX2 and
NANOG. However, similar to hBSCs and hESCs, OTBCs were
able to differentiate both in vitro and in vivo into cells from all
three germ layers, suggesting multi-lineage differentiation poten-
tial. Importantly, they were also able to differentiate into functional
lactocytes that synthesized milk proteins. These findings highlight
OCT4 with its associated embryonic TFs as potential key regula-
tors of normal self-renewal and differentiation in the breast during
pregnancy and lactation. Further, they suggest that deregulation
of OCT4 expression in the breast may result in malignant trans-
formation of breast cells, acquisition of tumorigenic properties,
and lactating differentiation potential.
MATERIALS AND METHODS
TISSUES
All tissues analyzed were biopsied specimens fixed in formalin
and embedded in paraffin. Normal human resting (N = 2) and
lactating (N = 6) breast tissues were obtained from the tissue
archive of the School of Anatomy, Physiology, and Human Biology,
The University of Western Australia. Human breast tumor tissues
were obtained from the Tissue Procurement Core Facility of The
University of North Carolina Lineberger Comprehensive Cancer
Center in accordance with approved institutional review board
(IRB) protocols. Tumor tissues were examined by a pathologist
and were identified as lactating breast adenomas (N = 7), lactat-
ing breast carcinomas (N = 3; two ductal carcinomas in situ grade
III from the same patient, and one invasive ductal carcinoma),
and PABC (N = 1). The tumor tissues were assigned lactating fea-
tures by the pathologist based on the presence of lipid droplets
characteristic of lactation. This was confirmed by immunofluo-
rescence (IF) staining for milk proteins both in the tumors and in
the normal lactating breast specimens (Figure 1). Positive controls
for comparison of ESC gene expression were seminoma speci-
mens obtained from the Tissue Procurement Core Facility of The
University of North Carolina Lineberger Comprehensive Can-
cer Center in accordance with approved IRB protocols. Human
tumors formed in nude/SCID mice in a xenograft assay from
OTBCs (Beltran et al., 2011) were used for IF staining for lactating
features and multi-lineage differentiation.
IMMUNOHISTOCHEMISTRY
Sections of 5-µm thickness were prepared for IHC analysis. IHC
was carried out in the Bond Autostainer (Leica Microsystems Inc.,
Norwell, MA, USA 02061). Slides were deparaffinized in Bond
Dewax solution (AR9222) and hydrated in Bond Wash solution
(AR9590). Heat induced epitope retrieval was performed at 100˚C
for 30 min in Bond-Epitope Retrieval solution 1 pH 6.0 (AR9961)
and blocked with Dako Serum-Free Ready-To-Use Protein Block
for 10 min (X0909). Slides were incubated with anti-OCT4 anti-
body (Table 1) for 2 h. Appropriate negative controls were also
prepared. Antibody detection was performed using the Bond
Polymer Refine Detection System (DS9800). Slides were coun-
terstained with hematoxylin. Stained sections were dehydrated in
a graded alcohol series, coverslipped, and imaged using the Ape-
rio Scanscope XT (Aperio Technologies, Vista, CA, USA 92081).
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FIGURE 1 | Expression of OCT4 in the normal resting and lactating
breast, and in breast tumors with lactating features or associated with
pregnancy and lactation. (A) IHC and IF staining of OCT4. Scale bars:
50µm (IHC) and 20µm (IF). Minimal and mostly cytoplasmic expression was
seen in the normal resting breast. During normal lactation, OCT4 was
upregulated and expressed in both the nucleus and cytoplasm, with varying
expression and subcellular localization between different tissues, and
between different lobules and alveoli within the same tissue. Enhanced
expression was observed in breast tumors with lactating features or
associated with pregnancy and lactation. In addition to the epithelium, some
expression was seen in the mammary stroma. (B) The lactating features of
the examined normal lactating and tumor tissues were confirmed via IF
staining for milk proteins and the presence of lipid droplets in the epithelium.
Scale bars: 10µm.
Seminoma tumors were used as positive control for staining qual-
ity and subcellular localization. Images were examined using the
Spectrum digital pathology platform.
IMAGE QUANTIFICATION
Image analysis was performed using the “Nuclei and Simulated
Cells” algorithm found in Definiens Tissue Studio software (ver-
sion 3.5; Munich, Germany). OCT4 expression was quantified
in two to five 0.9-µm2 squares per image, which were posi-
tioned in areas dominated by abnormal tissue. Epithelial and
stromal cells were digitally separated using a combination of Tissue
Studio Composer, an automated approach for Region of Interest
Selection (http://tissuestudio.definiens.com/composer.html), and
manual annotations. A first separation using Tissue Studio Com-
poser was followed by inspection of the annotation results and
manual adjustment of annotation using Manual Region of Inter-
est Selection for regions where the automated approach did not
yield appropriate annotation. The cellular analysis was identical
for the squares where Composer was used and those that were hand
annotated. For each square, expression in epithelial versus stromal
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Table 1 | Markers examined.
Marker Company Cat. no Applications
used
OCT4 Miltenyi (Stemgent) 130-095-635 FACS (1:100), IF
(1:100)
OCT4 Abcam ab18976 IHC (1:100-1:200),
IF (1:100)
NANOG Santa Cruz Biotech sc-33759 FACS (1:100), IF
(1:100)
NANOG Abcam ab80892 IF (1:100)
α-SMA Sigma-Aldrich A2547-0.2ML IHC (1:100)
CK14 Sapphire Bioscience GTX104124 IF (1:200)
CK18 Abcam ab32118 IF (1:100)
CK19 Thermo Scientific MA1-19059 IF (1:100)
EPCAM Exbio 11-581-C100 IF (1:300)
β-Casein Santa Cruz Biotech sc-53189 IF (1:100)
α-Lactalbumin Dako A057901 IF (1:1000)
β-III-tubulin Covance PRB-435P IF (1:1000)
Nestin Miltenyi (Stemgent) 130-095-648 IF (1:200)
Vimentin Sigma-Aldrich V5255 IF (1:100)
Desmin Sigma-Aldrich D1033-0.2ML IF (1:100)
Albumin Sigma-Aldrich A-3293 IF (1:200)
OV6 R&D Systems MAB2020 IF (1:200)
PDX1 Santa Cruz Biotech sc-14662 IF (1:100)
Insulin Santa Cruz Biotech sc-52040 IF (1:100)
Insulin Cell Signalling Tech 4590S IF (1:100)
C-peptide Cell Signalling Tech 4593S IF (1:100)
RUNX2 Santa Cruz Biotech sc-101145 IF (1:100)
OSX Santa Cruz Biotech sc-133871 IF (1:100)
Cardiac
T-troponin
Abcam ab45932 IF (1:100)
FACS, fluorescence activated cell sorting; IF, immunofluorescence; IHC, Immuno-
histochemistry.
cells was quantified, including information on positiveness (either
expression or no expression), subcellular localization (nuclear,
cytoplasmic, or both), and intensity of positive expression (low,
medium, or high). This was done via a cell scoring system that
grouped each cytoplasm into an intensity group (0, 1, 2, 3) and
each nucleus into an intensity group (100, 110, 120, 130). Then,
the two numbers were added together to give a unique score
based on the resulting sum (Table 2). For intensity measure-
ments, positive/negative thresholds were determined by visually
evaluating the above background intensity in a test group of
images. The test set had a range of cytoplasmic and nuclear DAB
intensities. The thresholds for medium and high intensity were
set at equal interval steps from the positive/negative. The sep-
aration of cytoplasms and nuclei was based on thresholds that
were determined for cytoplasms as 0.1 (minimum threshold), 0.3
(low to medium threshold), and 0.5 (medium to high threshold)
(Figure 2). For nuclei, compensation for the presence of hema-
toxylin and of a general brown background haze was done by
increasing the baseline to 0.5 as the minimum threshold, and
0.7 and 0.9 as the thresholds for medium and high intensity,
respectively. Example screenshots for this analysis are shown in
Table 2 | Scoring system for immunohistochemical quantification of
OCT4 expression in the breast tissues examined.
Cell score Nuclear status Cytoplasmic status
100 Negative Negative
101 Negative Low positive
102 Negative Medium positive
103 Negative High positive
110 Low positive Negative
111 Low positive Low positive
112 Low positive Medium positive
113 Low positive High positive
120 Medium positive Negative
121 Medium positive Low positive
122 Medium positive Medium positive
123 Medium positive High positive
130 High positive Negative
131 High positive Low positive
132 High positive Medium positive
133 High positive High positive
Figure 3. Results were compiled using Microsoft Excel (version
2010).
IMMUNOFLUORESCENCE
Immunofluorescence staining was done as described in Hassiotou
et al. (2012). Antibodies for ESC markers were standardized in
human fibroblasts (negative control cells). Briefly, adherent cells
were fixed in 1.5% paraformaraldehyde/0.7% sucrose in PBS, fol-
lowed by permeabilization in 0.1% Triton X in PBS and incubation
with primary (Table 1) and secondary antibodies (Alexa Fluor
488, 546, or 555 nm). hBSC and OTBC spheroids were fixed in 3%
formaldehyde in PBS, permeabilized in 0.1% PBS-Triton X 100,
washed in PBS, and stained with primary (Table 1) and secondary
(as above) antibodies. Five-micrometer thick sections of human
breast tissues and tumor tissues from the xenograft assays were
rehydrated in deionized water and incubated in PBS prior to per-
meabilization in 0.1% PBS-Triton X 100 and overnight incubation
with primary antibody (Table 1) in a humid chamber. Washing in
PBS and secondary antibody incubation for 2 h was followed by a
final wash and mounting (Dako). Imaging was standardized using
negative controls and was done in a Nikon Eclipse Ti inverted opti-
cal microscope, a Nikon 90i upright optical microscope, or a Leica
DMIRB Inverted Fluorescence/DIC microscope.
BREASTMILK COLLECTION AND CELL ISOLATION
The study protocol was approved by the Human Research Ethics
Office of The University of Western Australia. Breastmilk was
sourced from healthy breastfeeding women located in Perth, WA,
Australia. All participants (N = 31) provided informed written
consent and expressed mature breastmilk (5–200 ml) on one or
more occasions under aseptic conditions using a Medela Sym-
phony pump (Medela AG, Switzerland). Freshly expressed breast-
milk was diluted with equal volume of sterile PBS (pH 7.4,
Gibco, USA). After centrifugation at 805× g for 20 min at 20˚C,
the cell pellet was separated from the fat and liquid part skim
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A B C 
FIGURE 2 | Illustration showing part of the four image regions
used for optimization of nuclear and cytoplasmic sizes, shapes,
and IHC thresholds. Regions were chosen to include the range of
cytoplasmic and nuclear intensities that were present in the
complete image data set. Raw images (A) and corresponding
nuclear [hematoxylin; (B)] and IHC [DAB; (C)] stained layers are
shown. Arrows indicate examples of positive nuclei. Scale bar:
50µm.
milk, washed three times in PBS, and was then resuspended
in 7% Fetal Bovine Serum (FBS, Certified, Invitrogen, USA) in
PBS (blocking buffer). Total breastmilk cell content and viability
were measured using a Neubauer hemocytometer by Trypan Blue
exclusion.
FLOW ACTIVATED CELL SORTING
Ex vivo flow activated cell sorting (FACS) analysis of OCT4 and
NANOG expression in freshly isolated breastmilk cells was done
as described in Hassiotou et al. (2012). Antibodies against these
markers (Table 1) were standardized in human fibroblasts (neg-
ative control) and were shown to recognize their target proteins
by FACS (Stemgent, USA; Santa Cruz Biotechnology, USA). All
incubations and washes were done in 0.05% Tween-20 in PBS
after initial cell fixation in 1% paraformaraldehyde/0.7% sucrose
in PBS for 15 min. Primary antibody incubation was done for
30 min at 4˚C followed by secondary antibody incubation (Alex-
aFluor 488 nm for OCT4 and 647 nm for NANOG; Invitrogen,
USA) for 30 min at 4˚C at 1:300, final washing and suspension
into fixative. Appropriate secondary only negative internal con-
trols were used. Data acquisition was done with a FACS Calibur
Flow Cytometer (Becton Dickinson, NJ, USA) and data analysis
using FlowJo.
CELL LINES AND CELL CULTURE
OCT4-overexpressing tumorigenic breast cell lines were used from
Beltran et al. (2011) and cultured for examination of multi-
lineage differentiation as described for hBSCs by Hassiotou et al.
(2012). Freshly isolated breastmilk cells were cultured in spheroid
conditions as described previously (Hassiotou et al., 2012).
STATISTICAL ANALYSES
Statistical analyses were performed in Microsoft Excel and in R
2.9.0 1 for Mac OSX (R Development Core Team, 2009). The
results are presented as range and mean± SD. Ordinary least
squares regression models were used to determine whether levels
of expression differed between tissues types, with the percentage
of cells expressing OCT4 at the specified level as the response and
the tissue type classification as the predictor. Level of expression
was defined as the proportion of cells in each sample with posi-
tive expression of the given level (low, medium, high). Expression
for nucleus and cytoplasm was considered separately for each of
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FIGURE 3 | Representative examples of the examined tissues showing
cell type segmentation and cytoplasmic and nuclear classification for
different staining intensities used for quantification of OCT4 expression
in the epithelium and in the stroma. For each sample type, the top left
panel is the raw image; the top right illustrates the epithelial/stromal
segmentation with orange representing epithelial regions and blue the
stromal regions; the bottom left panel shows the cytoplasmic classification,
with white: negative cytoplasm, yellow: low positive cytoplasm, orange:
medium positive cytoplasm, red: highly positive cytoplasm; the bottom right
panel shows the nuclear classification, with blue: negative nucleus, yellow:
low positive nucleus, orange: medium positive nucleus, red: highly positive
nucleus. PABC: pregnancy-associated breast cancer. Scale bars: 100µm.
epithelial and stromal tissue. Tissues of the same type (normal
resting breast, normal lactating breast, lactating adenoma, lactat-
ing carcinoma, PABC) were grouped and comparisons were made
separately with respect to either the normal resting or the nor-
mal lactating breast. P values <0.05 were considered statistically
significant.
RESULTS
OCT4 AND NANOG ARE EXPRESSED IN THE NORMAL LACTATING
BREAST AND IN BREAST TUMORS WITH LACTATING FEATURES
Expression of OCT4 was examined by IHC and IF in the normal
breast during different stages of development (resting and lactat-
ing) and in breast tumors that display lactating features and/or
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are associated with pregnancy and lactation (Figure 1A). The lac-
tating properties of the examined tissues were confirmed via IF
staining for milk proteins and the presence of lipid droplets in
the epithelium (Figure 1B). OCT4 expression was detected both
in the epithelium and in the stroma, and typically higher expres-
sion levels in the epithelium corresponded with higher expression
levels in the stroma. However, stromal expression was generally
lower than that of the epithelium (Table 3; Figure 1). Levels of
expression varied within and between sample types, with different
proportions of cells expressing OCT4 in the nucleus, the cyto-
plasm, or both, and at various intensities, which were classified as
low, medium, or high (Figure 4). Despite these intra- and inter-
specimen variations, clear trends could be observed for each tissue
type (Figure 4). Minimal, and mostly low cytoplasmic, expression
was observed in the normal resting breast (range 0.07–0.09%;
mean 0.08± 0.02% SD nuclear expression), whilst an upregula-
tion in both total (range 32.6–88.5%; mean 57.7± 21.5% SD) and
nuclear (range 0.2–52.4%; mean 11.4± 20.5% SD) expression was
seen during normal lactation (Figures 1, 4, and 5; Table 3), with
large variation observed between different normal lactating breast
tissues. Of this, the highest expression was in the epithelium (range
0.1–78.7%; mean 16.1± 31% SD nuclear expression), but posi-
tive cells were also present in the stroma (range 0.3–26.1%; mean
6.8± 10.1% SD nuclear expression). OCT4 was localized both in
the ductal and alveolar lactating epithelium, and was scanty in
both the basal and luminal cell layers.
OCT4 nuclear expression was further upregulated in the breast
tumors examined, with the lactating adenomas showing the high-
est upregulation compared with the normal resting (P = 0.011)
and lactating breast (P = 0.007) (Table 3; Figure 4). Of note,
stronger expression in the epithelium of lactating adenomas was
observed in the basal layer compared with the luminal layer
(Figure 1). The PABC case examined showed one of the highest
OCT4 nuclear expressions, with marginally significant differences
with the normal resting (P = 0.043) and lactating breast (P = 0.07)
(Table 3; Figure 4). Significant increases in cytoplasmic OCT4
expression were also seen between the breast tumor tissues and
the normal resting (P = 0.008 for lactating adenomas; P = 0.019
for lactating carcinoma) and lactating breast tissues (P = 0.008
for lactating adenomas; P = 0.033 for lactating carcinoma), with
the highest expression observed in lactating adenomas (Table 3;
Figure 4). The increase in cytoplasmic expression in PABC was
marginally significant compared with the normal resting breast
(P = 0.061). OCT4 was co-localized with NANOG in the majority
of positive cells (Figure 6). In the normal resting breast tissues,
expression of NANOG was somewhat higher than that of OCT4,
but an upregulation was observed for both TFs in the normal
lactating breast (Figure 6). Similarly to OCT4, NANOG was also
upregulated in the tumor tissues examined and showed a pattern
of expression similar to OCT4 (Figure 6).
DIFFERENTIAL EXPRESSION OF OCT4 AND ASSOCIATED ESC GENES
BETWEEN NORMAL hBSCs AND OCT4-TRANSDUCED TUMORIGENIC
CELLS
To further examine differences in expression of OCT4 and associ-
ated ESC TFs between normal lactating breast stem cells and breast
CSCs, we took advantage of breastmilk as a source of stem cells
from the normal lactating breast, and of OCT4-overexpressing
breast cancer cell line models (OTBCs), given that cell lines
isolated from tumors that have high OCT4 expression are not
commercially available. Breastmilk cells were characterized ex
vivo by FACS for co-expression of OCT4 and NANOG. Mostly,
these TFs were co-expressed and levels of expression ranged 32–
88% of total breastmilk cells (Figure 7A), which is very similar
to the total expression levels observed in the normal lactating
breast tissues (Figure 4). An effect of lactation stage could be
seen on OCT4/NANOG protein expression in a cross-sectional
dataset of breastmilk samples, with a peak expression at 6 months
Table 3 | Mean levels and standard deviations (SD) of OCT4 expression in the tissues examined.
Nucleus Epithelial positive
(out of total epithelial)
Stromal positive
(out of total stromal)
Total positive
Mean (%) SD (%) Mean (%) SD (%) Mean SD
Resting breast (2) 0.1 0.0 1.7 2.0 0.9 1.0
Lactating breast (6) 16.1 31.0 6.8 10.1 11.4 20.5
Lactating carcinoma (3) 37.3 20.9 24.1 17.2 30.7 17.4
Lactating adenoma (7) 61.9 28.6 32.3 24.0 47.1 25.1
PABC (1) 72.0 – 24.7 – 48.3 –
Cytoplasm Mean (%) SD (%) Mean (%) SD (%) Mean (%) SD (%)
Resting breast (2) 62.4 35.6 13.1 1.7 37.7 16.9
Lactating breast (6) 79.0 17.4 41.7 24.5 57.5 21.4
Lactating carcinoma (3) 97.6 1.7 56.9 13.2 77.3 6.7
Lactating adenoma (7) 98.4 1.4 65.5 18.0 81.9 9.5
PABC (1) 98.6 – 69.1 – 83.9 –
Percentage positive epithelial cells (out of total epithelial cells), % positive stromal cells (out of total stromal cells), and % total positive cells were determined
separately for each sample. For each tissue type, N is shown in parentheses. Nuclear and cytoplasmic expressions are shown separately.
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FIGURE 4 | Quantification of OCT4 expression in the epithelium and
stroma of normal and tumor breast tissues. (A) Levels of expression
in the nucleus and cytoplasm between tissue types. Boxes show first
and third quartiles, horizontal bars within boxes indicate median values,
and “whiskers” show the range of values. Seminoma was used as
positive control. (B) Column charts showing contribution of the different
expression levels (low, medium, and high) to the total expression for
each tissue type. Significance is shown with stars, whereby black stars
compare the respective tissue with the normal resting breast and red
stars with the normal lactating breast. Normal human resting breast:
N =2; normal human lactating breast: N =6; lactating breast adenomas:
N =7; lactating breast carcinomas: N =3; pregnancy-associated breast
cancer (PABC): N =1. P values for overall levels of expression were
determined with OLS regression separately for each location and
comparison tissue, and are shown as: 0.05< ≤0.1; 0.01<*≤0.05;
and 0.001<**≤0.01.
Lactating adenoma Lactating carcinoma Seminoma 
Normal 
lactating breast 
FIGURE 5 | Additional examples of OCT4 expression by IHC and IF in the normal lactating and breast tumor tissues examined. Seminomas were used
as positive control. Scale bars: 50µm (IHC), and 10µm (IF).
postpartum, and a decrease in expression in later lactation
(Figure 7A). In spheroid culture conditions, hBSCs rapidly prolif-
erated to form spheroids that increased in size in a time-dependent
manner and co-expressed OCT4 and NANOG (Figure 7A).
RT-PCR analysis of mRNA expression of the ESC TF circuitry
(OCT4, SOX2, and NANOG) demonstrated an upregulation of
these genes in fresh breastmilk cells compared with resting breast
cells and fibroblasts, with the highest expression observed at
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FIGURE 6 | Co-localization of OCT4 (red) and NANOG (green) in the normal lactating breast and in breast tumors with lactating features or associated
with pregnancy and lactation. Scale bars: 20µm. Blue: DAPI stain for nuclei.
pregnancy concurrent with lactation (Figure 7B). Expression was
further increased in hBSC spheroids, which reached levels similar
to hESCs (Figure 7B) (Hassiotou et al., 2012).
OCT4-overexpressing tumorigenic breast cell lines acquired a
highly proliferative character compared with their parental cells,
which was enhanced in spheroid conditions (Figure 7B). Con-
current with OCT4, they showed upregulation of NANOG and to
a lesser degree of SOX2 (Figure 7B). However, both the absolute
and relative levels of ESC TF expression were markedly different in
OTBCs compared with hBSCs or hESCs. OCT4 mRNA expression
levels in OTBCs were 2–10 times higher than hESCs and breast-
milk spheroids, and 26–95 times higher than fresh breastmilk cells
(Figure 7B). SOX2 expression was markedly lower in OTBCs than
hESCs (230–753 times lower) or breastmilk-derived cells (33–281
times lower) (Figure 7B). NANOG expression was also lower in
OTBCs than hESCs (2–64 times lower) or breastmilk-derived cells
(4–130 times lower) (Figure 7B). These findings suggest differ-
ential expression of the ESC TF circuitry between normal breast
stem cells and breast CSCs.
OCT4-TRANSDUCED CELLS HAVE MULTI-LINEAGE DIFFERENTIATION
POTENTIAL
Given the function of OCT4 and its associated ESC TF cir-
cuitry in controlling the pluripotential of hESCs (Young, 2011),
it is of interest to examine whether expression of OCT4 by
breast cells is associated with multi-lineage differentiation prop-
erties. We have previously demonstrated that hBSCs can differ-
entiate into cells from all three germ layers both spontaneously
and under directed differentiation in specific microenvironments
(Hassiotou et al., 2012). Here, we examined the potential of
OTBCs to differentiate into mammary and non-mammary lin-
eages. Similarly to hBSCs, OTBCs were able to differentiate
into mammary ductal luminal CK19+ cells, SMA+ myoepithe-
lial cells, and lactocytes that produced β-casein under mammary
differentiation conditions. Furthermore, they also differentiated
into cells from non-mammary lineages, including β-III-tubulin
neuron-like cells, RUNX2+/OSX+ osteoblast-like cells, c-peptide-
producing islet-like cells, and T-troponin+ cardiomyocyte-like
cells (Figure 8A). Of note, due to the propagation of OTBCs
in spheroid culture, later passages acquired a migratory charac-
ter and were less adhesive; hence differentiation efficiency was
greater in earlier passages of OTBCs rather than in later pas-
sages. In addition, we examined multi-lineage differentiation of
OTBCs in the tumors that these cells generated when injected
in nude/SCID mice. Despite the relatively poor differentiation
state of these tumors, areas with differentiated morphology and
phenotype were detected via staining for lineage-specific markers
(Figure 8B). These included epithelial markers such as CK14 and
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analysis of OCT4 and NANOG co-expression in freshly isolated breastmilk
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In addition, hBSC spheroids obtained in 3D culture that co-express OCT4 and
NANOG are shown. Blue: DAPI nuclear stain. Scale bars: 20µm. (B) The
Workflow of derivation of OCT4-transduced cells (OTBCs) from resting breast
cells is shown (adapted from Beltran et al., 2011). The IF images present
OTBC spheroids grown in 3D culture expressing OCT4 and NANOG. Blue:
DAPI nuclear stain. The column chart compares mRNA expression levels of
OCT4, SOX2, NANOG, and KLF4 among parental lines (p1 and p2), OTBC
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(N =16), fresh milk cells during pregnancy [“Milk cells (pregnancy),” N = 1],
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EPCAM, with some cells being positive for milk proteins, suggest-
ing lactating features (Figure 8B). The neural markers nestin and
β-III-tubulin were also expressed (Figure 8B). Mesodermal mark-
ers such as vimentin, desmin, SMA, and the osteoblast phenotype
RUNX2/OSX were expressed (Figure 8B). Endodermal lineage
cells were also present, including cells expressing the endodermal
progenitor marker OV6 and the islet marker PDX1 (Figure 8B). In
addition, areas with the distinct phenotypes OV6high/PDX1−/low
and OV6−/low/PDX1high were detected (Figure 8B), suggesting
different stages of differentiation within a tumor. These results
suggest that expression of OCT4, either normal or aberrant,
is associated with multi-lineage differentiation potential and
conferral of lactating features.
DISCUSSION
Molecular determinants of lactation features and aberrant cell
proliferation by some breast tumors are not well understood. Here,
we confirm and extend previous findings of expression of ESC
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self-renewal TFs in both normal lactation and breast cancer. We
have previously reported upregulation of OCT4 and its associated
ESC genes in the normal lactating breast and breastmilk-derived
stem cells (Hassiotou et al., 2012). This prompted us to examine
expression of OCT4 in breast tumors with lactating features and
compare it with the normal breast. We found that OCT4 is physi-
ologically upregulated during lactation compared with the resting
breast, suggesting a potential role of this gene and its associated
ESC gene network in the normal mammary stem cell (MaSC) self-
renewal that fuels the remodeling of the breast into a fully mature
milk-secretory organ. The association of OCT4 with lactation was
further demonstrated by its aberrant expression in breast tumors
with lactating features, in which expression levels were significantly
higher than in the normal breast (P < 0.01). Some of these tumors
may be associated with pregnancy and lactation, although further
research is needed to underpin the molecular characteristics of
these tumors. Comparison of normal hBSCs with tumorigenic
OCT4-tranduced cells showed differential expression of ESC TFs
in the two systems. We propose that the levels and balance of
expression of ESC TFs in breast cells distinguish between a nor-
mal and a CSC (Figure 9). Expression of OCT4 in both normal and
CSCs appears to be associated with lactation features and multi-
lineage differentiation capabilities, in accordance with the role of
these TFs in maintaining pluripotency in ESCs and iPSCs.
A unifying feature between the normal lactating breast and
the examined breast tumors was upregulation of OCT4, which
was co-localized with NANOG in the majority of positive cells.
In contrast to the normal resting breast, where expression of
OCT4 and NANOG were minimal, mostly in cytoplasms and at
low levels, lactating features both in the normal and transformed
breast were associated with upregulation of these TFs, particu-
larly in the nucleus. Cytoplasmic staining for ESC TFs in the
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A
B
FIGURE 9 | Proposed model of mammary cellular hierarchy integrating
expression of OCT4 and its associated embryonic stem cell gene
network in the regulation of self-renewal, differentiation, and
transformation in the breast. (A) The resting breast is characterized by
minimal expression of the ESC TF circuitry, which allows maintenance of
quiescence and low self-renewal activity in MaSCs. During pregnancy and
lactation and under physiologic cues, OCT4 promoter becomes activated
effecting transient activation of other ESC TFs and downstream targets. This
regulates a controlled program of MaSC expansion and subsequent
differentiation. Uncontrolled overexpression of OCT4 and/or its associated
ESC TFs leads to oncogenic activation of TFs, transformation, and aberrant
expansion of the target cell, which may be a MaSC or a more differentiated
cell, and acquisition of a CSC phenotype. (B) Normal and aberrant mammary
epithelial hierarchy based on changing expression of OCT4 that determines
the cell state in a mammary developmental continuum. Deregulation of OCT4
expression at each developmental state results in cell transformation and
generation of different tumor subtypes. DECs, differentiated epithelial cells;
CSCs, cancer stem cells.
breast has also been reported previously (Lengerke et al., 2011),
and may be suggestive of either non-specific/background staining
or true cytoplasmic expression indicative of a different function,
isoform, and/or transcriptional/post-transcriptional regulation of
these genes in the cytoplasm. The latter is further supported by the
shift toward nuclear expression in the lactating tissues, and merits
further investigation.
Significant variation in OCT4 expression was observed among
the normal lactating breast tissues examined, which is in agree-
ment with the variable expression levels detected in breastmilk-
derived cells (Hassiotou et al., 2012). Here, we show some evi-
dence that this variation may be related to the stage of lac-
tation (Figure 7A). Moreover, differential expression was seen
within each tissue, with some lobules and alveoli showing higher
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expression than others. This demonstrates a heterogeneity in cell
differentiation and maturation between and within different lob-
ules within a breast, as has been reported for other species (Mole-
naar et al., 1992), and suggests that variations observed between
breastmilk samples may at least in part reflect emptying of specific
lobules during the milk expression process.
In agreement with the association of these TFs with lactation,
tumors with lactating features showed upregulation of OCT4, but
with much higher expression than the normal lactating epithelium
(P < 0.05), often concentrated in the basal layer. This suggests that
OCT4 confers a tumorigenic character when expressed at levels
higher than the normal range. In support of this, forced ectopic
expression of OCT4 in resting breast cells produced cells with high
proliferation capacity that resembled the claudin-low subtype, and
which formed primary tumors and metastases in nude/SCID mice
(Beltran et al., 2011). By contrast, hBSCs, which originate from
the normal lactating breast, did not form tumors when injected
subcutaneously in SCID mice (Hassiotou et al., 2012). When
compared with hBSCs and hESCs, OTBCs had markedly higher
expression of OCT4 and lower expression of SOX2 and NANOG
(Figure 7B). These TFs were expressed at similar levels in each of
hESCs and cells from the normal lactating breast, but this balance
was completely deregulated in OTBCs (Figure 7B).
Taken together, these results suggest that the distinguishing fac-
tor between normal MaSCs and breast CSCs may be the balance
between and expression levels of TFs, which control breast cell
self-renewal. These findings are integrated in Figure 9A, which
proposes a model by which expression levels of the pluripotency TF
circuitry control MaSC self-renewal, differentiation, and aberrant
transformation. At the same time, regulation of other TFs associ-
ated with these genes as well as their downstream targets may con-
tribute to the normal versus aberrant stem cell self-renewal. To this
end, two recent studies reported significantly lower disease-free
survival in patients with strong OCT4 and NANOG expression,
and better survival rates in patients with high KLF4 expression (Liu
et al., 2011; Nagata et al., 2012). KLF4 acts in concert with OCT4,
SOX2, and NANOG in hESCs (Young, 2011), but is downregulated
in some breast cancer cells compared with normal mammary cells
(Akaogi et al., 2009). Interestingly, KLF4 expression was higher in
breastmilk-derived cells than in OTBCs and hESCs (Figure 7D).
This may in part explain the non-tumorigenic character of nor-
mal MaSCs and of hBSCs (Hassiotou et al., 2012) in contrast to
OTBCs and hESC lines (Lensch et al., 2007; Beltran et al., 2011),
suggesting that high KLF4 expression may be a protective factor
against aberrant cell proliferation during normal lactation.
In addition to self-renewal, OCT4, SOX2, and NANOG con-
trol pluripotency in hESCs and iPSCs (Takahashi et al., 2007;
Young, 2011). This prompted us to examine whether hBSCs and
OTBCs, which both express these genes, have multi-lineage dif-
ferentiation potential. Indeed, we have previously shown that
hBSCs can differentiate into cells with properties of functional
ectodermally-, mesodermally-, and endodermally-derived cells
(Hassiotou et al., 2012). Here, we show that similarly to hBSCs,
OTBCs are able to differentiate into cells from the three germ lay-
ers, including functional lactocyte-like cells that synthesized milk
proteins, and islet-like cells, myoepithelial cells, neuron-like cells,
osteoblast-like cells, and cardiomyocyte-like cells, with phenotype
and morphology of the corresponding cell lineages (Figure 8B).
Further, OTBC-originated tumors in nude/SCID mice contained
cells with phenotypes from different lineages, including cells that
synthesized milk proteins (Figure 8B). Of note, only certain
cell subpopulations underwent differentiation in these xenograft
tumors, while the remaining cells were in a poor differentiation
state, possibly due to their high level of OCT4 expression. We
propose that expression of this TF pluripotency network, either
in normal MaSCs or in transformed MaSCs, confers lactation
features under mammary conditions and multi-lineage differ-
entiation capabilities in tissue-specific microenvironments. This
notion may provide insight into the origin and properties of meta-
plastic breast tumors as well as mechanisms behind breast cancer
metastasis. The presence of OCT4+/NANOG+ cells in the mam-
mary stroma both in the normal lactating and the tumor tissues
examined (Figures 1 and 4) further supports this theory, suggest-
ing that self-renewal and differentiation in the mammary stroma
may be controlled by the same TF network that regulates the mam-
mary epithelium. This gene network may differentially respond
to different micro-environmental cues to control lineage-specific
differentiation.
To our knowledge, this is the first study that directly com-
pares ESC TF expression and subcellular localization between
normal lactation and breast cancer, enabling a first examination
of expression differences in these rare specimens. A limitation of
the current data is the number of samples available for IHC analy-
sis. However, normal human lactating breast tissue specimens are
extremely rare,which is why the normal human lactating breast has
been scarcely studied previously. Similarly, although breast tumor
tissues with lactating features may not be as rare as previously
thought, pathologists do not routinely look for and designate lac-
tating features in tumor samples, rendering the acquisition of such
samples problematic. Further studies are needed to confirm and
expand the current findings, also including normal breast samples
during early, middle and late pregnancy, to improve understand-
ing of ESC TF expression during the normal pregnancy/lactation
cycle.
An important outcome of our study was the demonstration
of ESC TF expression changes in different developmental stages
of the normal adult breast. Previous focus on the resting breast,
where MaSCs are scarce (Tiede and Kang, 2011) and these TFs
are silenced (Lengerke et al., 2011), has hindered examination of a
role of these genes in mammary development. We showed a phys-
iological upregulation of these genes during lactation, opening
new avenues for investigation of their function during mammary
development, such as associations with lactation efficiency and
postpartum involution. At the same time, these TFs may be used as
new candidate markers for delineation of the cellular hierarchy of
the mammary gland, which has been problematic due to impreci-
sion of the current markers known to identify different mammary
subpopulations (Prat and Perou, 2009). Figure 9B proposes a sim-
plified model of normal and aberrant mammary hierarchy based
on expression of OCT4. The varying expression and subcellular
localization of OCT4 both in the normal lactating breast and in the
examined breast tumors together with the relatively small propor-
tion of highly positive cells in the nucleus in all cases suggest that
OCT4 is differentially expressed along a differentiation continuum
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of the mammary cellular hierarchy, with distinct expression lev-
els and subcellular localization in different cell developmental
states, and strongest expression in MaSCs. This model gives further
insight into the CSC theory, proposing that differential aberrant
upregulation of OCT4 and its associated ESC genes together with
the developmental state of the targeted cell may explain tumor
heterogeneity and the different breast cancer subtypes. This is
consistent with previous studies suggesting differential cellular
origins of the different breast cancer subtypes (Lim et al., 2009;
Prat and Perou, 2009; Thomas et al., 2012). Future studies will
utilize breastmilk as a non-invasive and personalized source of the
cellular hierarchy of the fully mature gland to study the normal
biology of this organ, molecular determinants of breast cancer,
and potentially breast cancer risk.
CONCLUSION
OCT4 and its associated embryonic TFs emerge as potential reg-
ulators of self-renewal and potency in early-stage MaSCs, which
are scarce in the resting breast, but are activated to undergo a
controlled program of proliferation and differentiation toward
milk-secretory cells during pregnancy and lactation. In addition
to their role during normal lactation, these genes may control
breast oncogenesis by reverting normal mammary cells to a CSC
self-renewing phenotype when expressed aberrantly. It is proposed
that disruption of this controlled program of gene expression dur-
ing pregnancy and lactation, failure to appropriately silence these
genes during postpartum involution, and/or their aberrant imbal-
anced upregulation in the resting breast can be at the origin and
progression of aggressive breast cancers, which may display lac-
tating features. Future work will utilize the cellular hierarchy of
breastmilk as a model to elucidate genetic events that transform
cells along the mammary developmental continuum to give rise to
different subtypes of breast cancer.
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